Study Confirms MDMA Is Stable on Zydis® ODT and Suitable for Pre-Gastric Absorption TORONTO, CANADA, October 04, 2023 – Awakn Life Sciences Corp. (NEO: AWKN, OTCQB: AWKNF, FSE: 954) (“Awakn”), a clinical…

Announces Closing of Third Tranche of Private Placement TORONTO, CANADA, September 14, 2023 – Awakn Life Sciences Corp. (NEO: AWKN, OTCQB: AWKNF, FSE: 954) (“Awakn”), a clinical-stage biotechnology company developing therapeutics to…

AWAKN-P001 Is a N-methyl-D-aspartate Receptor-Modulating Drug Used in Combination with Psycho-Social Support for The Treatment of Severe Alcohol Use Disorder TORONTO, CANADA, Sept 6, 2023 – Awakn Life Sciences Corp. (NEO:…

Sale Completes Awakn’s Exit From Healthcare Services To Focus Solely on Biotechnology Research and Development TORONTO, CANADA, Aug 1, 2023 – Awakn Life Sciences Corp. (NEO: AWKN, OTCQB: AWKNF, FSE: 954)…

Licenses Awakn Kare and Certain Healthcare Intellectual Property Assets to New Owners TORONTO, CANADA, July 5, 2023 – Awakn Life Sciences Corp. (NEO: AWKN, OTCQB: AWKNF, FSE: 954) (“Awakn” or the…

TORONTO, CANADA, June 27, 2023 – Awakn Life Sciences Corp. (NEO: AWKN, OTCQB: AWKNF, FSE: 954) (the “Company”), a clinical-stage biotechnology company developing therapeutics to treat addiction with a near-term focus on…

Conference hosted by M-Vest, Awakn to present on Thursday, June 22nd at 9:00 A.M. ET  TORONTO, CANADA, June 19, 2023 – Awakn Life Sciences Corp. (NEO: AWKN, OTCQB: AWKNF, FSE: 954) (the…

TORONTO, CANADA, June 15, 2023 – Awakn Life Sciences Corp. (NEO: AWKN, OTCQB: AWKNF, FSE: 954) (the “Company”), a clinical-stage biotechnology company developing therapeutics to treat addiction with a near-term focus on…

Term Sheet Signed to License Healthcare Intellectual Property to UK Healthcare Consortium Exclusively in the UK Market Strategic Review of Norwegian Healthcare Clinics Business Unit Initiated TORONTO, CANADA, June 9,…

Annual Revenue Increased by 534% TORONTO, CANADA, April 28, 2023 – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (‘Awakn’), a biotechnology company developing therapeutics to treat addiction with a…

TORONTO, CANADA, April 26, 2023 – Awakn Life Sciences Corp. (NEO: AWKN, OTCQB: AWKNF, FSE: 954) (the “Company”), a biotechnology company developing therapeutics to treat addiction with a near-term focus on Alcohol…

Phase III Trial will Assess Ketamine-Assisted Therapy for The Treatment of Severe Alcohol Use Disorder TORONTO, CANADA, 18 April, 2023 – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (‘Awakn’), a…